Anixa Biosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Anixa Biosciences Inc (NASDAQ:ANIX) operates as a clinical-stage biotechnology company focused on developing therapies and vaccines for cancer treatment and prevention. The company offers a therapeutics portfolio featuring chimeric endocrine receptor T-cell (CER-T) immunotherapy, including liraltagene autoleucel (lira-cel), an FSHR-targeted CAR-T therapy exclusively licensed from The Wistar Institute for recurrent ovarian cancer, conducted in Phase 1 trials with Moffitt Cancer Center; its vaccine portfolio, developed with Cleveland Clinic, targets retired proteins in triple negative breast cancer (TNBC), ovarian cancer, and additional programs for lung, colon, and prostate cancers. Founded in 1982 and headquartered in San Jose, California, Anixa conducts operations primarily in the United States through collaborations with leading research institutions. Recent developments include World Health Organization approval in November 2025 of the international non-proprietary name liraltagene autoleucel for its CAR-T therapy, marking a milestone toward commercialization; expansion in May 2024 of its Cleveland Clinic partnership for novel cancer vaccines; a $5 million share repurchase program authorized in July 2024; and a letter of intent with VERDI Solutions for artificial intelligence applications in development.
Company News
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares
Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for July 22nd
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance